Abdelrahman Ali
@Abdelcards
Followers
463
Following
875
Media
42
Statuses
324
Cardiology Fellow @utmbcardiology | #CardioOncology via @MDAndersonNews |ICOS Certified @ICOSociety | Husband & Father | Tweets are my own.
Houston, TX
Joined September 2018
1/10🚨 Huge thanks to @JACCJournals for highlighting our work on risk stratification in #HER2+ breast cancer patients 🫀🎗️ We explore how the HFA/IC-OS tool can help optimize care without compromising safety. Let’s dissect the paper! 🔍📄#CardioOnc #CardioTwitter #JACCCardioOnc.
Risk assessment through HFA/IC-OS stratification tool in breast cancer patients undergoing #HER2-inhibitors: the way for optimizing resource use without compromising cardiovascular safety? #JACCCardioOnc #CardioOnc #BCsm #LVEF
2
4
15
RT @avirupguha: Invitation to all #AI #cardioonc #radiomics colleagues to please submit to this special. DM for questions. @ICOSociety @drb….
0
6
0
RT @ICOSociety: 🚨NEW PODCAST🚨 In February, the Exercise Working Group published an article in the @ESC_Journals on #CORE. We sat down with….
0
3
0
RT @ICOSociety: 🎙️✨ New Podcast Alert! Join us as @ShadenKhalaf from @MDAndersonNews dives into 🫀 pericardial disease in cancer patients —….
0
5
0
RT @ICOSociety: On this episode of #HeartToHeart, we're joined by @itsnot_pink of @CancerGrasp. Julia shares her treatment journey with I….
0
4
0
RT @HJRyooAli: Case presented at ACC #CardioOnc 2025. #PulmonaryHypertension in patients with metastatic cancer? Consider lung scintigraphy….
0
5
0
RT @JAHA_AHA: Baseline ECG provides incremental value to clinical variables for risk prediction of cancer therapy-related cardiac dysfuncti….
0
12
0
RT @ICOSociety: 🚨NEW PODCAST🚨 @cezar_ciliescu of @MDAndersonNews dropped by the podcast to chat about his work on managing pericardial dis….
0
4
0
RT @TDonisan: Truly grateful for the chance to be part of this session with such inspiring colleagues and mentors @mayocvonc @cezar_ciliesc….
0
5
0
RT @AabuzaidDr: Coming and promising research for Cardiac PET to detect early cardiovascular toxicity @ICOSociety @MyASNC @JNCjournal….
0
5
0
RT @drtarsh: Absolutely thrilled to have been part of a delegation from @RBandH along with my esteemed colleagues # DrAlexlyon @sohaibnazi….
0
4
0
An incredible experience at the 2nd Middle East #CardioOncology Congress in 🌟Dubai🌟! Honored to present and collaborate with @HSkouri & @AabuzaidDr 🙏. Representing @ICOSociety was a true privilege! 🚀🎗️ Grateful for the support 🙌 @anita_deswal, @docHJ, and @cezar_ciliescu 🌟
0
4
28
10/10 Grateful to our amazing team—especially my mentor @anita_deswal 🙏🙏.This work is dedicated to Dr. Daniel Booser, a champion of personalized care. Thank you @PalaskasN @DrDebuTripathy @AnaBaracCardio @EKoutroumpakis.#CardioOnc #CardioTwitter #JACCCardioOnc.
0
1
3
9/10 .🧠 Our findings support a personalized, risk-based LVEF monitoring strategy . 📌 Using HFA/IC-OS, CTRCD risk varied by profile. 🟢 No HF in low/moderate-risk pts w/o anthracyclines. ✅ De-escalation may optimize care & resource use. #CardioOnc #CardioTwitter #HER2 #BCSM
1
1
2
8/10.📈 The HFA/IC-OS tool showed good discrimination: AUC = 0.71 in both overall and trastuzumab-only groups. ✅ Calibration was strongest in low/moderate-risk groups. 🛡️ NPV for CTRCD in low-risk:.96.4% (all pts) & 96.8% (trastuzumab-only).#CardioOnc #CardioTwitter #HER2 #BCSM
1
0
0
7/10.📊 Using the HFA/IC-OS tool, CTRCD occurred in:. 🟢 Low-risk: 3.6%. 🟡 Moderate-risk: 12.8%. 🔴 High-risk: 32.1%. 🧠 HF was rare in low/moderate risk (0.4%, 2.1%) but 11% in high-risk. #CardioOnc #HER2 #CardioTwitter #BCSM #BreastCancerResearch
1
0
0
6/10.🧪 CTRCD occurred in 8.7% over a median follow-up of 51.2 months. 📉 Median time to CTRCD: 8 months.💔 Symptomatic HF in 1.6%.📈 Higher CTRCD in those receiving anthracyclines:.14.2% vs 6.3% (P=0.004); HF: 3.4% vs 0.9% (P=0.055).#CardioOnc #HER2 #CardioTwitter #BCSM
1
0
0
5/10.📊 Mean age: 52 years. 🧬Baseline LVEF <55% in 4.4%. 🩺Comorbidities: HTN (34%), DM (12%), Obesity (38%). 🫀History of HF: 1.8%.These risk factors were more prevalent in patients who developed CTRCD. #CardioOnc #CardioTwitter #JACCCardioOnc #BCSM #BreastCancerResearch
1
0
0
4/10 We retrospectively studied 496 women with #HER2+ breast cancer at @MDAndersonNews 🎗️🫀 treated with trastuzumab ± anthracyclines. Goals:.1️⃣ Assess rates of symptomatic/asymptomatic CTRCD.2️⃣ Evaluate HFA/IC-OS tool for risk-based monitoring.#CardioOnc #CardioTwitter
1
1
1
3/10 Early trials combining trastuzumab with anthracyclines showed 🚨 high cardiotoxicity—28% had cardiac dysfunction, 19% developed NYHA III/IV HF 🫀 Even with sequential use, CTRCD remains a major concern. #CardioOnc #HER2 #Cardiotwitter
1
0
0
2/10 🚺 Trastuzumab has transformed #HER2+ breast cancer outcomes—but comes with a risk 🫀 of CTRCD. Guidelines recommend frequent LVEF checks, yet risk may not be uniform. We asked: Can we tailor monitoring using the HFA/IC-OS tool? Let’s find out 👇 #CardioOnc #cardiotwitter
1
0
0